INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10806871		
Filing Date		2004-03-22		
First Named Inventor	Inventor Dimpsey et al.			
Art Unit		2185		
Examiner Name Savia		a, Arpan P.		
Attorney Docket Number		AUS920040064US1		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5966538		1999-10-12	Granston et al.	
	2	5940618		1999-08-17	Blandy et al.	
	3	6189142	B1	2001-02-13	Johnston et al.	
	4	5768500		1998-06-16	Agrawal et al.	
	5	6026235		2000-02-15	Shaughnessy	
	6	5950003		1999-09-07	Kaneshiro et al.	
	7	6594820	B1	2003-07-15	Ungar	
If you wis	h to a	dd additional U.S. Pat	ent citatio	n information p	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10806871	
Filing Date		2004-03-22	
First Named Inventor	Dimpsey et al.		
Art Unit		2185	
Examiner Name Savla		, Arpan P.	
Attorney Docket Number		AUS920040064US1	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1	20020073406	A1	2002-0	6-13	Gove					
	2	20030066055	A1	2003-0	4-03	Spivey					
	3	20030131343	A1	2002-0	7-10	French et al.					
	4	20040268316	A1	2004-17	2-30	Fisher et al.					
If you wisi	h to a	dd additional U.S. Publi:						d buttor	$\overline{}$		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³		Country Code ⁴ Date Name of Patentee or Applicant of cited Document Passages or Release or Appearance of Passages or Release or Rel			evant or Relevant	тя			
	1										
If you wis	h to a	d additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*						Тs					
	1										
If you wish	f you wish to add additional non-patent literature document citation information please click the Add button Add										

	Application Number		10806871	
INFORMATION DIGGS COURT	Filing Date		2004-03-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dimp		psey et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		2185	
(NOTION SAUSINGSSON GROCE OF OTHER 1884)	Examiner Name Savia		vla, Arpan P.	
	Attorney Docket Numb	er	AUS920040064US1	

EXAMINER SIGNATURE							
Examiner Signature		Date Considered					
*EXAMINER: Initial if	reference considered, whether or not citation is in conforma	nce with MPEP 609	. Draw line through a				

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Pittent Documents at years USPTO.GDV or MPEP 901.04. Finiter office that issued the document, by the two-letfer code (WIPO Standard STS). For Juponese plant documents, the advisation of the year of the right of the Employed must precise the sent number of the patient document. Program of the patient document and patient document

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10806871	
Filing Date		2004-03-22	
First Named Inventor	Dimpsey et al.		
Art Unit		2185	
Examiner Name Savla		, Arpan P.	
Attorney Docket Number		AUS920040064US1	

CERTIFICATION STATEMENT

Please see 3/	CFR 1.97 and	1.98 to make the	appropnate selection	h(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) the statement of the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) and the statement of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-10-05
Name/Print	Gerald H. Glanzman	Registration Number	25035

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.